Interventions: VK2735 Primary Outcome Measure: Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment Time Frame: 78 weeks Study Details Source VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) Sponsor: Viking Therapeutics Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
10.4103/0974-2077.104912 209 SarkarR.ChughS.GargV
Under California Vehicle Code 23152, a BAC of 0.08% or more indicates that you are too intoxicated to drive
In a healthy individual, the enzymes DAO and HNMT act as a drain at the bottom of the bucket, efficiently clearing histamine as fast as it accumulates, keeping the overall level safely below the brim